GLPG vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GLPG presents a classic 'value trap' profile: while the Graham Number ($84.09) and Intrinsic Value ($163.14) suggest massive undervaluation, the Piotroski F-Score of 2/9 indicates severely weak fundamental health. The company boasts a pristine balance sheet with zero debt and an extraordinary current ratio of 20.14, yet the market is pricing it at a 66% discount to its defensive fair value. This discrepancy, combined with a negative forward P/E and a 0/100 technical trend, suggests the market anticipates a significant reversal of recent growth spikes.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GLPG vs LLY: Head-to-Head Comparison
This page compares Galapagos NV (GLPG) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.